2024年9月4日 · Raloxifene (Evista) belongs to a class of drugs called selective estrogen receptor modulators (SERMs). It is FDA-approved for the prevention and treatment of osteoporosis in postmenopausal...

SERMs and osteoporosis. Osteoporosis affects approximately 8 million women and people AFAB in the U.S. SERMs may slow bone loss and reduce risk of fractures in women with osteoporosis. Are SERMs common treatments? Yes, they are. Healthcare providers typically prescribe SERMs to prevent and/or treat ER-positive breast cancer.

Some SERMs, such as raloxifene and bazedoxifene, have estrogen activity in bone and, therefore, prevent bone loss, improve bone mineral density (BMD), and decrease the risk of …

2020年7月13日 · SERMs are often used to treat estrogen-related conditions, such as infertility, osteoporosis, and some types of breast cancer. Some people refer to SERMs as designer estrogen because they can...

2023年1月20日 · Raloxifene (Evista) is part of a class of drugs known as selective estrogen-receptor modulators (SERMs). It works by imitating the beneficial effects of the hormone estrogen on your bones,...

Consistent with preclinical observations, this new SERM demonstrated improved skeletal efficacy over raloxifene and at an oral dose of 0.5 mg/day was effective in the prevention of both vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.

2023年9月15日 · SERMS like Evista (raloxifene) can help improve bone density in people with osteoporosis. It can prevent low bone density from becoming osteoporosis and reduces the risk of vertebral fractures. They act by turning down the bone cells in charge of breaking down bone and reabsorbing its nutrients.

Selective estrogen receptor modulators (SERMs) are a new class of drugs that provide a new option for addressing the health challenges of postmenopausal women. This review discusses the proposed mechanism of action of SERMs and describes clinical findings on raloxifene, a SERM now available for treating and preventing osteoporosis. KEY POINTS

Newer SERMs are currently undergoing clinical investigation for the management of postmenopausal conditions associated with estrogen deficiency, particularly osteoporosis. This update describes the most recent literature on SERMs to evaluate their safety and efficacy on the treatment of postmenopausal osteoporosis.

2016年10月4日 · Selective estrogen receptor modulators (SERMs) are now being used as a treatment for breast cancer, osteoporosis and postmenopausal symptoms, as these drugs have features that can act as an estrogen agonist and an antagonist, depending on the target tissue.